Couraud S, et al. - In order to determine chemotherapy outcomes in patients with stage IV non–small-cell lung cancer (NSCLC) and BRAF V600 mutations, researchers performed a case-control analysis using data from the French Cooperative Thoracic Intergroup Biomarkers France study, a national prospective cohort study describing the molecular characteristics and clinical outcome of all consecutive NSCLC patients (N = 17,664) screened for molecular alterations. Patients with stage IV BRAF-mutated (BRAF-MT) NSCLC were included as cases whereas those with NSCLC that was wild-type for EGFR, KRAS, HER2, BRAF, PIK3CA and ALK were included as controls. Findings suggest no strong prognostic value of BRAF mutation in NSCLC. Despite poorest progression-free survival in correlation to taxan-based therapy in first-line, no chemotherapy regimen was identified to be associated with prognosis.